Literature DB >> 1295528

Haemangiopericytoma of the orbit.

T J Sullivan1, J E Wright, A E Wulc, A Garner, I Moseley, N Sathananthan.   

Abstract

Orbital haemangiopericytomas are ideally managed by complete surgical excision in the first instance. This is frequently not achieved, because difficulty in making the diagnosis preoperatively results in incisional biopsy and the highly vascular nature of the tumour makes complete excision difficult. A series of 12 patients with orbital haemangiopericytoma seen over a 23-year period is presented. The following combination of clinical and radiological features is suggestive of haemangiopericytoma. 1. Painless non-axial proptosis with downward displacement of the globe. 2. Intermittent upper lid swelling. 3. A soft, superiorly located mass with poorly defined borders, especially with a blue hue. 4. A superiorly located, rounded or elongated extraconal mass on CT, isodense with brain, with smooth, well-defined borders and moderate to marked enhancement with the injection of intravenous contrast medium. 5. Significant blush in all three phases of carotid angiography, without prominent arteriovenous shunting. Once haemangiopericytoma is suspected, complete surgical excision is recommended.

Entities:  

Mesh:

Year:  1992        PMID: 1295528     DOI: 10.1111/j.1442-9071.1992.tb00745.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  3 in total

1.  Treatment of recurrent orbital haemangiopericytoma with surgery and proton beam therapy.

Authors:  H C Gear; E G Kemp; A Kacperek; R D Errington
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

2.  Neuroradiological features of intracranial and intraorbital meningeal haemangiopericytomas.

Authors:  J Ruscalleda; M Feliciani; A Avila; E Castañer; E Guardia; M de Juan
Journal:  Neuroradiology       Date:  1994-08       Impact factor: 2.804

3.  Vascular tumors of the orbit.

Authors:  I Günalp; K Gündüz
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.